Choosing the right registration pathway for the China drug master file: an essential analysis of options


Building upon the foundational insights presented in the first article of our China series, this subsequent piece delves deeper into the intricacies of China’s drug master file (DMF) registration pathways. Focused on active pharmaceutical ingredients (API), excipient and packaging material products, this article provides a crucial analysis of these pathway options.

By illuminating the advantages and considerations inherent in each of the options, this article aims to empower DMF applicants with the knowledge necessary to strategically optimise their registration processes within the dynamic regulatory environment of China. This comprehensive exploration serves as a valuable resource for industry professionals seeking to navigate and excel in DMF registration in China.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.



Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account


TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member